UB Paderborn / Katalog / Suche / in CDI

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

The New England journal of medicine, 2018-07, Vol.379 (1), p.11-21

2018

Link zum Volltext

Verfügbarkeit prüfen

Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study

Neurology, 2015-08, Vol.85 (8), p.675

2015

Link zum Volltext

Verfügbarkeit prüfen

Statin-related adverse events: A meta-analysis

Clinical therapeutics, 2006, Vol.28 (1), p.26-35

2006

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease

Cholesterol, 2010, Vol.2010, p.383281-11

2010

Link zum Volltext

Verfügbarkeit prüfen

Impact of a pharmacist on drug costs in a coronary care unit

American journal of health-system pharmacy, 2001-03, Vol.58 (6), p.497-502

2001

Link zum Volltext

Verfügbarkeit prüfen

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

Leukemia & lymphoma, 2012-03, Vol.53 (3), p.435-440

2012

Link zum Volltext

Verfügbarkeit prüfen

Aspirin resistance and genetic polymorphisms

Journal of thrombosis and thrombolysis, 2002-08, Vol.14 (1), p.51-58

2002

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a Phase 3 study of patisiran

Revue neurologique, 2019-04, Vol.175, p.S129-S129

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: Potential clinical implications

Journal of thrombosis and thrombolysis, 2003-06, Vol.15 (3), p.217-225

2003

Link zum Volltext

Verfügbarkeit prüfen

Possible mechanisms of drug-induced aspirin and clopidogrel resistance

Journal of thrombosis and thrombolysis, 2006-10, Vol.22 (2), p.139-150

2006

Link zum Volltext

Verfügbarkeit prüfen

HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein

American journal of health-system pharmacy, 2004-08, Vol.61 (16), p.1676-1681

2004

Link zum Volltext

Verfügbarkeit prüfen

Possible mechanisms of aspirin resistance

Journal of thrombosis and thrombolysis, 2002-02, Vol.13 (1), p.49-56

2002

Link zum Volltext

Verfügbarkeit prüfen

Antifactor Xa Levels in Four Patients with Burn Injuries Who Received Enoxaparin to Prevent Venous Thromboembolism

Pharmacotherapy, 2004-12, Vol.24 (12), p.1793-1799

2004

Link zum Volltext

Verfügbarkeit prüfen

Myocardial infarction in an adolescent taking Adderall

American journal of health-system pharmacy, 2005-07, Vol.62 (14), p.1494-1497

2005

Link zum Volltext

Verfügbarkeit prüfen

Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient

American journal of health-system pharmacy, 2003-12, Vol.60 (23), p.2479-2483

2003

Link zum Volltext

Verfügbarkeit prüfen

Sirolimus-eluting coronary stent

American journal of health-system pharmacy, 2004-03, Vol.61 (5), p.449-456

2004

Link zum Volltext

Verfügbarkeit prüfen

Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents

Current cardiology reports, 2003-07, Vol.5 (4), p.310-317

2003

Link zum Volltext

Verfügbarkeit prüfen

A review of the clinical uses of ximelagatran in thrombosis syndromes

Journal of thrombosis and thrombolysis, 2003-12, Vol.16 (3), p.175-188

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure

Journal of thrombosis and thrombolysis, 2001-02, Vol.11 (1), p.39-48

2001

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

Vascular health and risk management, 2006, Vol.2 (1), p.39-48

2006

Link zum Volltext

Verfügbarkeit prüfen

A synopsis of the clinical uses of argatroban

Journal of thrombosis and thrombolysis, 2001-10, Vol.12 (2), p.141-149

2001

Link zum Volltext

Verfügbarkeit prüfen

Recommended and actual lepirudin doses in patients with renal insufficiency

American journal of health-system pharmacy, 2003-12, Vol.60 (24), p.2588-2593

2003

Link zum Volltext

Verfügbarkeit prüfen

Polymorphism induced sensitivity to warfarin: A review of the literature

Journal of thrombosis and thrombolysis, 2003-06, Vol.15 (3), p.205-212

2003

Link zum Volltext

Verfügbarkeit prüfen

CD40 ligand: a novel target in the fight against cardiovascular disease

The Annals of pharmacotherapy, 2004-09, Vol.38 (9), p.1500

2004

Link zum Volltext

Verfügbarkeit prüfen

Recommended and actual lepirudin doses in patients with renal insufficiency

American journal of health-system pharmacy, 2004-03, Vol.61 (5), p.437-437

2004

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study

Statin-related adverse events: A meta-analysis

Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease

Impact of a pharmacist on drug costs in a coronary care unit

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

Aspirin resistance and genetic polymorphisms

Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a Phase 3 study of patisiran

Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: Potential clinical implications

Possible mechanisms of drug-induced aspirin and clopidogrel resistance

HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein

Possible mechanisms of aspirin resistance

Antifactor Xa Levels in Four Patients with Burn Injuries Who Received Enoxaparin to Prevent Venous Thromboembolism

Myocardial infarction in an adolescent taking Adderall

Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient

Sirolimus-eluting coronary stent

Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents

A review of the clinical uses of ximelagatran in thrombosis syndromes

Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

A synopsis of the clinical uses of argatroban

Recommended and actual lepirudin doses in patients with renal insufficiency

Polymorphism induced sensitivity to warfarin: A review of the literature

CD40 ligand: a novel target in the fight against cardiovascular disease

Recommended and actual lepirudin doses in patients with renal insufficiency

Suchergebnisse filtern